Affiliation:
1. Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Tokyo, Japan.
Abstract
Butenafine is a new antifungal benzylamine. The efficacy of butenafine was investigated in an experimental tinea pedis model in guinea pigs, which is pathologically similar to natural infections in humans. Butenafine (0.1 ml) in 0.2 to 1.0% solutions was applied to the site of infection. Treatment was started on day 10 postinfection and was continued for 20 days. Butenafine applied once daily exhibited excellent dose-related therapeutic efficacy. The efficacy of butenafine was significantly superior to those tolnaftate, clotrimazole, and bifonazole.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference4 articles.
1. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs;Arika T.;Antimicrob. Agents Chemother.,1990
2. Experimental tinea pedis by non-abrasive inoculation of Trichophyton mentagrophytes arthrospores on the plantar part of guinea pig foot;Fujita S.;J. Med. Vet. Mycol.,1987
3. In vivo antimycotic activity of naftifine;Petranyi G.;Antimicrob. Agents Chemother.,1981
4. Takahashi H. A. Hasegawa 0. Kaneko A. Saito and Y. Tanaka. 1986. Clinical studies of fungicidal agents with respect to their relationship in vitro and in vivo p. 227-240. In K. Iwata and H. Vanden Bossche (ed.) In vitro and in vivo evaluation of antifungal agents. Elsevier Science Publishers Amsterdam.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献